|
|
|
|
|
|
The team collectively:
|
|
|
|
over 100 years of successful experience across health care value chain, including general management, corporate strategy, research, new product development, pharmaceutical medicine, business development, marketing and finance
|
|
|
| – |
Drs. Buhler, Drews and Ryser, as the Biomedicine Team, led the investment of more than $70 million in two dozen venture and private equity transactions from 1997-2000.
|
| – |
Ms. Czerepak, Dr. Drews and Dr. Ryser played significant roles, either separately or in collaboration, in over 30 health care corporate transactions valued at more than $10 billion.
|
| – |
Drs. Buhler, Drews and Ryser were three founding partners of International Biomedicine Management
Partners ("IBMP").
|
|
|
Building Upon the Experience of International Biomedicine Management Partners
|
|
|
| – |
Fully invested in 13 diversified biotech companies; brought 7 public.
|
| – |
Portfolio companies span key disciplines including research, drug discovery, clinical development and market launch. Focus on:
– New technologies that create value in biomedicine
– New medicines that satisfy medical needs and create economic value
|
| – |
Access to an international network of scientific, medical, regulatory, academic, business and financial relationships.
|
|
|
|
|
Successful Investing and Operating Records
|
|
Comprehensive knowledge and expertise in medicine, biological sciences and venture capital
|
|
